Literature DB >> 24510525

Influence of the freeze-drying process on the physicochemical and biological properties of pre-heated amphotericin B micellar systems.

Scheyla D V S Siqueira1, Miguel A Silva-Filho, Christian A Silva, Ivonete B Araújo, Acarilia E Silva, Matheus F Fernandes-Pedrosa, Anselmo G Oliveira, E Sócrates T Egito.   

Abstract

The moderate heat treatment of amphotericin B (AmB) in its micellar form (M-AmB) results in superaggregates (H-AmB) that present a substantially lower toxicity and similar activity. The aim of this work was to evaluate the H-AmB behavior after a freeze-drying process. H-AmB and M-AmB micelles were evaluated before and after freeze-drying concerning their physicochemical and biological properties by spectrophotometry and activity/toxicity assay, respectively. Four concentrations of M-AmB and H-AmB were studied aiming to correlate their aggregation state and the respective biological behavior: 50 mg L(-1), 5 mg L(-1), 0.5 mg L(-1), and 0.05 mg L(-1). Then, potassium leakage and hemoglobin leakage from red blood cells were used to evaluate the acute and chronic toxicity, respectively. The efficacy of M-AmB and H-AmB formulations was assessed by potassium leakage from Candida albicans and by the broth microdilution method. After heating, in addition to an evident turbidity, a slight blueshift from 327 to 323 nm was also observed at the concentrations of 50 and 5 mg L(-1) for H-AmB. Additionally, an increase in the absorbance at 323 nm at the concentration of 0.5 mg L(-1) was detected. Concerning the toxicity, H-AmB caused significantly lower hemoglobin leakage than M-AmB. These results were observed for H-AmB before and after freeze-drying. However, there was no difference between H-AmB and M-AmB concerning their activity. Accordingly, the freeze-drying cycle did not show any influence on the behavior of heated formulations, highlighting the suitability of such a method to produce a new AmB product with a long shelf life and with both greater efficiency and less toxicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24510525      PMCID: PMC4037496          DOI: 10.1208/s12249-014-0085-z

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  35 in total

1.  Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.

Authors:  E W Van Etten; L E Stearne-Cullen; M ten Kate; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B.

Authors:  J Brajtburg; S Elberg; D R Schwartz; A Vertut-Croquin; D Schlessinger; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

3.  Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form.

Authors:  B Baas; K Kindt; A Scott; J Scott; P Mikulecky; S C Hartsel
Journal:  AAPS PharmSci       Date:  1999

Review 4.  Current role of therapy with amphotericin B.

Authors:  R D Meyer
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

5.  Amphotericin B/emulsion admixture interactions: an approach concerning the reduction of amphotericin B toxicity.

Authors:  E Sócrates T Egito; Ivonete B Araújo; Bolivar P G L Damasceno; James C Price
Journal:  J Pharm Sci       Date:  2002-11       Impact factor: 3.534

6.  Amphotericin B microemulsion reduces toxicity and maintains the efficacy as an antifungal product.

Authors:  Bolívar P G L Damasceno; Victor A Dominici; Isabel A Urbano; José A Silva; Ivonete B Araújo; Nereide S Santos-Magalhães; Amanda K A Silva; Aldo C Medeiros; Anselmo G Oliveira; E Sócrates T Egito
Journal:  J Biomed Nanotechnol       Date:  2012-04       Impact factor: 4.099

7.  Prevalence of HIV infection in provincial prisons in British Columbia.

Authors:  D A Rothon; R G Mathias; M T Schechter
Journal:  CMAJ       Date:  1994-09-15       Impact factor: 8.262

8.  Stability and transdermal absorption of topical amphotericin B liposome formulations.

Authors:  A Manosroi; L Kongkaneramit; J Manosroi
Journal:  Int J Pharm       Date:  2004-02-11       Impact factor: 5.875

Review 9.  Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.

Authors:  Thomas P C Dorlo; Manica Balasegaram; Jos H Beijnen; Peter J de Vries
Journal:  J Antimicrob Chemother       Date:  2012-07-24       Impact factor: 5.790

10.  Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774.

Authors:  Monique Chéron; Caroline Petit; Jacques Bolard; François Gaboriau
Journal:  J Antimicrob Chemother       Date:  2003-11-12       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.